What to Expect at ASCO 2026 —Translating Science to Practice

The American Society of Clinical Oncology (ASCO) Annual Meeting returns to Chicago’s McCormick Place and online from May 29 to June 2, 2026, under the theme ‘The Science and Practice of Translation: Improving Cancer Outcomes Worldwide.‘

More than 44,000 oncology professionals will gather to explore over 3,400 abstracts and late-breaking clinical trials, with a program set to redefine standards of care across multiple cancer types.

Late-Breaking Abstracts: What Will Shape Clinical Practice?
Ahead of the annual meeting, we’ve reviewed some of the late-breaking abstracts poised to influence practice in breast, colorectal, prostate, and lung cancer, as well as metastatic uveal melanoma—a disease long without effective systemic therapy. Among the most anticipated:

• VIKTORIA-1 (NCT05501886): Results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant (Faslodex®; AstraZeneca) with or without palbociclib (Ibrance®; Pfizer) in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), PIK3CA mutant locally advanced or metastatic breast cancer (ABC), following progression on or after treatment with a CDK4/6 inhibitor and an aromatase inhibitor. (Abstract LBA1008)[1]
• BREAKWATER (NCT04607421): Reports the first overall survival results in BRAF^V600E-mutant colorectal cancer. The encorafenib (Braftovi®; Pfizer)  + cetuximab + mFOLFOX6 regimen achieved a median OS of 30.3 months, compared with 15.1 months for standard of care, representing a 51% reduction in the risk of death (Hazard Ratio 0.49). Detailed results will be presented in a late-breaking abstract. The BREAKWATER study brings biomarker-driven combinations to the forefront, with promising survival gains for BRAF-mutated disease. Clinicians are seeking insights into durability, subgroup benefits, and the speed at which these therapies can move into standard care. (LBA3503) [2]
• Metastatic Uveal Melanoma: New systemic therapies are under the spotlight after decades without breakthroughs.  A late-breaking abstract/oral presentation will provide the complete data from the Phase 2/3 registrational trial (OptimUM-02; NCT05987332) of darovasertib in combination with crizotinib (Xalkori®; Pfizer) in first-line (1L) HLA*A2-negative metastatic uveal melanoma. (LBA9503)[3]

Major phase 3 data will also spotlight clinical advances in prostate, pancreatic, and multiple myeloma, with trials that could shift standards of care and move powerful therapies earlier in treatment.

Lung Cancer: Precision Moves Earlier, Immunotherapy Gets Smarter
Non-small Cell Lung Cancer (NSCLC) is at the vanguard of this year’s practice-changing science. Results from studies such as LIBRETTO-432 and HARMONi-6 build on existing understanding, allowing researchers to deploy targeted therapies earlier in the treatment line and make immunotherapy smarter.

• LIBRETTO-432 (NCT04819100): A global phase 3 study evaluating selpercatinib (Retevmo®; Eli Lilly and Company; formerly known as LOXO-292) pushes precision medicine into the post-surgical, adjuvant setting for patients with rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). This represents an important change in cancer treatment. Updated results will be presented in the Late Breaking Abstract (LBA3) during the plenary session. [4]
• HARMONi-6 (NCT05840016): A randomized controlled, multi-center, open-label phase 3 study showcasing the first-in-class bispecific immunotherapy ivonescimab (also known as AK112), designed to simultaneously target PD-1 and VEGF, combined with platinum-based chemotherapy versus tislelizumab (Tevimbra®; BeOne Medicines) combined with platinum-based chemoimmunotherapy in patients with stage IIIB/C or stage IV (metastatic) squamous NSCLC. The focus of the late-breaking presentation at ASCO 2026 is on mature overall survival (OS) data to assess whether ivonescimab’s dual PD-1/VEGF targeting translates into a meaningful long-term survival benefit. Updated results will be presented during the plenary session (Abstract LBA4).[5]

Prostate Cancer: Redefining Perioperative Management
Results from the phase 3 PROTEUS trial (NCT03767244) could transform surgery-based management in high-risk localized prostate cancer by testing whether hormonal manipulation with apalutamide combined with androgen deprivation therapy (ADT) in men with high-risk localized prostate cancer who are undergoing radical prostatectomy improves long-term outcomes. The results of the study’s final analysis will be presented during the plenary session (Abstract LBA1). [6]

Pancreatic Cancer: Potential Breakthroughs
Results from the Phase 3 RASolute 302 trial (NCT06625320) comparing daraxonrasib (formerly known as RMC-6236), a first-in-class, investigational oral medication that acts as a ‘molecular glue’ and binds to cyclophilin A to block the signaling of multiple RAS-mutant variants (G12/G13/Q61), versus standard chemotherapy in heavily pre-treated metastatic pancreatic ductal adenocarcinoma (mPDAC) are highly anticipated. Early reports from monotherapy and combination trials demonstrated profound tumor shrinkage and a doubling of the median overall survival compared with historical chemotherapy benchmarks. Additional pan-KRAS inhibitor data will also be presented, with the focus on durability, safety, and application to earlier disease stages.  The data will be presented during the penary session (LBA5).[7]

Multiple Myeloma: Expanding Options and Access
Multiple myeloma is seeing a surge in new therapies:

• MAJESTEC-3 (NCT05083169)/MAJESTEC-9 (NCT05572515): Results of a phase 3 multicenter, open-label study investigating teclistamab (Tecvayli®; Johnson & Johnson), a bispecific T-cell engager (BiTE) that binds to BCMA on myeloma cells and CD3 on T-cells, in patients diagnosed with relapsed or refractory multiple myeloma who received  1 to 3 prior lines of treatment, will be presented (Abstract 7507) [8]
• CARTITUDE-4 (NCT04181827): Results from this phase 3 trial investigating ciltacabtagene autoleucel (also known as JNJ-68284528 and JNJ-4528), an investigational BCMA-directed Chimeric Antigen Receptor T Cell (CAR-T) therapy for the treatment of relapsed or refractory multiple myeloma, are expected to have this therapy shift to second-line therapy, while in vivo CAR T-cell therapy is heralded as a practice-changing approach in CAR T-cell therapy.[Abstract 7536][9]
• In 2025, a major focus was on engineering CAR T-cells to overcome solid-tumor barriers (such as the suppressive microenvironment) and prevent on-target, off-tumor toxicities. The spotlight was on synthetic logic-gated designs and in vivo manufacturing next-generation CAR T-cell engineering, including logic-gated (Tmod) and in vivo approaches, with a focus on solid tumors and reduced toxicity.  During the upcoming annual meeting, expect updated results from the ongoing phase 1/2 EVEREST-2 clinical study (NCT06051695) investigating the safety and efficacy of A2B694 and A2B543, logic-gated mesothelin (MSLN)-targeted Tmod™ CAR T-therapies designed to selectively kill tumor cells and protect normal cells via a dual-receptor design consisting of an activator that targets tumor cells and a blocker that protects normal cells (Abstract 8579 and TPS2673) [10][11]

Liposarcoma: Building on the biological rationale of CDK4 amplification
SARC041 (NCT04967521): Results of a phase 3 randomized double-blind study of abemaciclib (Verzenio®; Eli Lilly and Company) versus placebo in patients with advanced dedifferentiated liposarcoma, a rare and aggressive sarcoma subtype with limited treatment options, will be presented as part of the penary session (LBA2). The highly anticipated data will reveal whether targeted cell-cycle inhibition may improve outcomes in these patients.[12]

Conditionally Active Biologic (CAB) in advanced solid tumors
Results from a multi-center, open-label, Phase 1/2 study (NCT03425279) of mecbotamab vedotin (BA3011), a CAB-platform antibody-drug conjugate (ADC) targeting AXL, a receptor tyrosine kinase overexpressed in many solid tumors that has been shown to be associated with treatment resistance and poor clinical outcomes, alone and in combination with nivolumab (Opdivo®; Bristol-Myers Squibb) in adult and adolescent patients 12 years and older, are highly anticipated. Data presented in late 2025 demonstrated the potential of mecbotamab vedotin to meaningfully extend survival in patients with treatment-refractory soft tissue sarcomas. (Abstract 11511)[13]

Oncology’s Momentum: More Options, More Complexity
As part of the presentations, we’re especially watching for results from studies focusing on antibody-drug conjugates (ADCs) and strategies for sequencing and combination with immunotherapies, especially in bladder, breast cancer, and lung cancer

Bladder Cancer

• NEXUS-01 (NCT06465069). In a phase 1 study of LY4052031, a next-generation antibody-drug conjugate (ADC) targeting Nectin-4 in patients with advanced or metastatic urothelial carcinoma, showed promising clinical activity at multiple dose levels, including in patients previously treated with enfortumab Vedotin (Padcev®; Astellas and Pfizer)(Abstract 4508)[14]
• KEYNOTE-B15/EC-304 (NCT04700124): Results from this closely watched study, designed to assess the antitumor efficacy and safety of perioperative enfortumab plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy). (Abstract 4614)[15]

Breast Cancer:

• JSKN016-101 (NCT06592417): a dose-escalation and dose-expansion clinical study enrolling patients with advanced solid tumors to receive JSKN016 monotherapy, a next-generation TROP2/HER3 targeting bispecific ADC developed using the proprietary single-domain antibody and bispecific antibody platforms. The investigational drug is conjugated via site-specific glycosylation to produce a homogeneous, stable drug with a drug-to-antibody ratio (DAR) of 4. JSKN016 binds to TROP2 and/or HER3 on tumor cells and releases topoisomerase I inhibitors through cellular endocytosis, exerting anti-tumor effects. In earlier studies, JSKN016 demonstrated very promising efficacy and a superior safety profile among patients with late-line breast cancer. The results guarantee the further development of JSKN016, in combination with chemotherapy in front-line and perioperative settings. The 2026 ASCO Annual Meeting will feature the presentation of analytical results from the HER2-negative breast cancer cohort of this study. (Abstract 1123)[16]

Lung cancer

• OptiTROP-Lung05 study (NCT06448312). Results from the planned interim analysis of sacituzumab tirumotecan (previously known as SKB264 and MK-2870) in combination with pembrolizumab (Keytruda®; Merck & Co/MSD) demonstrated a reduced risk of progression or death by 65% and the risk of death by 45% compared with pembrolizumab alone in patients with treatment-naive, PD-L1-positive advanced NSCLC. (Abstract 8506).[17]

Looking Ahead: Turning Momentum Into Clarity
The 2026 ASCO Annual Meeting offers a comprehensive look at how more precise, less toxic, and more accessible therapies are shaping the future of cancer care. The challenge for clinicians will be to turn this momentum into clarity—analyzing new data, debating standards, and ultimately improving patient outcomes.

Track all accepted trials and late-breaking updates on the ASCO Annual Meeting portal as the oncology community prepares for a pivotal week in cancer science and patient care.

Clinical trials
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/​HER2- Breast Cancer (VIKTORIA-1) – ClinicalTrials.gov ID NCT05501886
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
ClinicalTrials.gov ID NCT04607421
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma – ClinicalTrials.gov ID NCT05987332
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) – ClinicalTrials.gov ID NCT04819100
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer – ClinicalTrials.gov ID NCT05840016
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS) – ClinicalTrials.gov ID NCT03767244
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma – ClinicalTrials.gov ID NCT04967521
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302) – ClinicalTrials.gov ID NCT06625320
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma – ClinicalTrials.gov ID NCT03425279
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors – ClinicalTrials.gov ID NCT06592417
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3) – ClinicalTrials.gov ID NCT05083169
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9) – ClinicalTrials.gov ID NCT05572515
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4) – ClinicalTrials.gov ID NCT04181827
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) – ClinicalTrials.gov ID NCT06051695
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) – ClinicalTrials.gov ID NCT06465069
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/​ KEYNOTE-B15 /​ EV-304) (KEYNOTE-B15) – ClinicalTrials.gov ID NCT04700124
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) – ClinicalTrials.gov ID NCT06465069
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer – ClinicalTrials.gov ID NCT06448312

Highlights of Prescribing Information
Fulvestrant (Faslodex®; AstraZeneca)[Prescribing Information]
Palbociclib (Ibrance®; Pfizer)[Prescribing Information]
Encorafenib (Braftovi®; Pfizer)[Prescribing information]
Selpercatinib, (Retevmo®; Eli Lilly and Company)[Prescribing Information]
Abemaciclib (Verzenio®; Eli Lilly and Company)[Prescribing Information]
Nivolumab (Opdivo®; Bristol-Myers Squibb)[Prescribing Information]
Teclistamab (Tecvayli®; Johnson & Johnson)[Prescribing Information]
Pembrolizumab (Keytruda®; Merck & Co/MSD)[Prescribing Information]
Enfortumab Vedotin (Padcev®; Astellas and Pfizer)[Prescribing information]

References
[1] Hurvitz SA, Curigliano G, Andre F, Layman RM, Wesolowski R, Cristofanilli M, Martin M, Ring AE, Puig JM, Richardet ME, Shin J, Kim SB, Liu LC, Rosselli G, Mutka S, Cacovean A, Suzuki S, Sullivan B, Gorbatchevsky I, Pistilli B. A randomized, open-label, phase 3 study of gedatolisib + fulvestrant ± palbociclib vs standard of care in HR+/HER2−/PIK3CA-mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2). J Clin Oncol 44, 2026 (suppl 17; abstr LBA1008) DOI: 10.1200/JCO.2026.44.17_suppl.LBA1008
[2] Kopetz S, Tabernero J, Lonardi S, Shen L, Wasan HS, Yoshino T, Van Cutsem E, Kim TW, Eng C, Ciardiello F, Desai J, Maughan T, Yaeger R, Usari T, Zhang X, Beyzarov E, Mori A, Whalley E, Zhang X, Elez E. BREAKWATER: Progression-free and overall survival analyses of firstline (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600Emutant metastatic colorectal cancer (mCRC). J Clin Oncol 44, 2026 (suppl 17; abstr LBA3503) DOI: 10.1200/JCO.2026.44.17_suppl.LBA3503
[3] Orloff MM, Ramelyte E, Butler MO, Rutkowski P, Di Guardo L, Carlino MS, Chmielowski B, Kennedy LB, Montazeri K, Sacco JJ, Rossi E, Atkinson V, Haq R, McKean M, Cole GW, Patel H, Kwei L, Sachdev JC, Beaupre DM, Piperno-Neumann S.Darovasertib plus crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial. J Clin Oncol 44, 2026 (suppl 17; abstr LBA9503). DOI: 10.1200/JCO.2026.44.17_suppl.LBA9503
[4] Goldman JW, Yang X, Hochmair M, Wu L, Kim HR, Paz-Ares LG, Rieke DT, Johnson ML, Yang JCH, Tsuboi M, Besse B, Sharma N, Maeda PH, Peterson P, Frimodt-Moller B, Yang Y, Drilon AE, Wu YL. Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial. J Clin Oncol 44, 2026 (suppl 17; abstr LBA3) DOI: 10.1200/JCO.2026.44.17_suppl.LBA3
[5] Zhiwei C, Yang F, Luo Y, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Shi Q, Ma X, Ma X, Zhang Z, Xia MY, Lu S. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.J Clin Oncol 44, 2026 (suppl 17; abstr LBA4) DOI: 10.1200/JCO.2026.44.17_suppl.LBA4
[6] Taplin ME, Gleave M, Shore ND, Lopez-Gitlitz A, Kretschmer A, Efstathiou E, Damião R, Kamoto T, Ross A, Briganti A, Hadaschik BA, Heidenreich A, Soto AJ, Rooney OB, Tian SK, Wetherhold L, Miladinovic B, McCarthy S, Evans CP, Kibel AS. Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study. J Clin Oncol 44, 2026 (suppl 17; abstr LBA1). DOI: 10.1200/JCO.2026.44.17_suppl.LBA1
[7] Wolpin BM, Wainberg ZA, Hendifar A, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, O’Reilly EM. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study. J Clin Oncol 44, 2026 (suppl 17; abstr LBA5). DOI: 10.1200/JCO.2026.44.17_suppl.LBA5.
[8] Mina R, Touzeau C, Hungria V, Landgren CO, Bhutani D, Chen W, Kumar S, Chaulagain CP, Dimopoulos MA, Bahlis NJJ, Maral S, Van de Donk NW, Saja K, Teipel R, Ando M, Wang D, Wroblewski S, Shah P, Chastain K, Quach H. MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM). J Clin Oncol 44, 2026 (suppl 16; abstr 7507) DOI: 10.1200/JCO.2026.44.16_suppl.7507.
[9] Mina R, Van de Donk NW, Touzeau C, Cohen YC, Weisel KC, Roeloffzen W, De Larrea CF, Ishida T, Ho PJ, Ghosh A, Benachour N, Lonardi C, Li Q,
Balogh A, Koskinen S, Lendvai N, Patel N, Rodríguez-Otero P, Callander NS, Manier S. Ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma responding to bridging therapy: CARTITUDE-4 cytogenetic subgroup analysis. J Clin Oncol 44, 2026 (suppl 16; abstr 7536). DOI: 10.1200/JCO.2026.44.16_suppl.7536
[10] Molina JE, Ward J, Hecht JR, Kirtane K, Marar R, Fankuchen OR, Mitchell J, Maloney DG, Maus MV, Eng C, Hazim AZ, Patel SP, Dorigo O, He K, Lou Y, Kundranda MN, Vu P, Xuan JD, Avila M, Punekar SR. Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)–targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH). J Clin Oncol 44, 2026 (suppl 16; abstr 8579). DOI: 10.1200/JCO.2026.44.16_suppl.8579
[11] Punekar SR, Patel SP, Botta GP, Ward J, Kirtane K, Prasad DK, Leal A, Ulrickson M, Specht JM, Zhen DB, Lou Y, Avila M, He K, Dorigo O, Eng C, Mitchell J, Mardiros A, Welch JS, Molina JR, Hecht JR. A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study. J Clin Oncol 44, 2026 (suppl 16; abstr TPS2673). DOI: 10.1200/JCO.2026.44.16_suppl.TPS2673
[12] Dickson MA, Ballman KV, Weiss MC, Attia S, Wagner MJ, Pollack SM, Choy E, Wagner AJ, Wilky BA, Davis LE, Riedel RF, Koff A, Tap WD. SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. J Clin Oncol 44, 2026 (suppl 17; abstr LBA2). DOI: 10.1200/JCO.2026.44.17_suppl.LBA2
[13] Conley AP, Pollack SM, Druta M, Tap WD, Yen CC, Charlson JA, Davis LE, Chalmers AW, Loggers ET, Grewal JS, Falchook GS, Schulte B,  Yau T, Kim A, Loong HH, George S, Setty B, Mascarenhas L, Cote GM, Wilky BA. Overall survival analysis of a heavily pretreated population of patients with bone sarcomas treated with mecbotamab vedotin, a conditionally binding ADC targeting AXL. J Clin Oncol 44, 2026 (suppl 16; abstr 11511). DOI: 10.1200/JCO.2026.44.16_suppl.11511
[14] Iyer G, Gao X, Wei AZ, Park I, Muro K, O’Donnell PH, Garmezy B, Galsky MD, Joshua AM, Patnaik A, Lakhani NJ, Gonzalez AF, Gauna DC, Philipovskiy A, Call JA, Tripathi A, Chang AE, Martin EA, Han H, Powles T. Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma. J Clin Oncol 44, 2026 (suppl 16; abstr 4508). DOI: 10.1200/JCO.2026.44.16_suppl.4508
[15] Hoimes CJ, Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu TE, Chatzkel JA, Koie T, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Wirtz H, Mihm M, Huang Q, Rogiers A, Moreno BH, De Liaño Lista AG. Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.J Clin Oncol 44, 2026 (suppl 16; abstr 4614). DOI: 10.1200/JCO.2026.44.16_suppl.4614
[16] Yao H, Huang Z, Zong H, Yan M, Zhao Y, Tong Z, Liu J, Wang J, Cao Y, Zhang Q, Han X, Sun L, Wu X, Shi J, Tang J, Wen J, Yu H, Su F, Zhou H, Dang Q. JSKN016, a first-in-class anti-TROP2/HER3 bispecific antibody-drug conjugate (ADC), in patients (pts) with HER2-negative locally advanced or metastatic breast cancer: Results from a phase I study. J Clin Oncol 44, 2026 (suppl 16; abstr 1123). DOI: 10.1200/JCO.2026.44.16_suppl.1123.
[17] Zhou C, Xiong A, Yao W, Zheng W, Yu Y, Chen P, Zhong H, Wang H, Chen B, Wang H, Fan Y, Yang Y, Pu X, Wang Q, Song X, Huang Z, Du XB, Qing Y, Jin X, Ge J. Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study. J Clin Oncol 44, 2026 (suppl 16; abstr 8506). DOI: 10.1200/JCO.2026.44.16_suppl.8506

Featured image: 2023 ASCO Annual Meeting.  Photo courtesy © 2023 – 2026 ASCO/Nick Agro. Used with permission.

DOI